D'Avolio A - Search Results

1

Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects.

Ranzani A, Castelli F, Di Biagio A, d'Arminio Monforte A, D'Avolio A, Soria A, Bai F, Focà E, Taramasso L, Calcagno A, Bresciani E, Torsello A, Bonfanti P, Lapadula G. Ranzani A, et al. HIV Med. 2024 Apr;25(4):491-497. doi: 10.1111/hiv.13600. Epub 2023 Dec 17. HIV Med. 2024. PMID: 38104964

2

Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.

González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. González de Requena D, et al. AIDS. 2006 Oct 3;20(15):1977-9. doi: 10.1097/01.aids.0000247121.19951.fa. AIDS. 2006. PMID: 16988521

3

Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid".

Calcagno A, D'Avolio A, Di Perri G, Bonora S. Calcagno A, et al. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):e118-9. doi: 10.1097/QAI.0b013e3182809d9f. J Acquir Immune Defic Syndr. 2013. PMID: 24135736 No abstract available.

4

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Nozza S, et al. J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23. J Antimicrob Chemother. 2014. PMID: 24458511 No abstract available.

5

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A, Bonora S. Calcagno A, et al. Clin Infect Dis. 2015 Jan 15;60(2):311-7. doi: 10.1093/cid/ciu773. Epub 2014 Oct 3. Clin Infect Dis. 2015. PMID: 25281609 Free article.

6

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.

Calcagno A, D'Avolio A, Bonora S. Calcagno A, et al. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1167-76. doi: 10.1517/17425255.2015.1056732. Expert Opin Drug Metab Toxicol. 2015. PMID: 26073580 Review.

7

Efavirenz pharmacogenetics in a cohort of Italian patients.

Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Cusato J, et al. Int J Antimicrob Agents. 2016 Feb;47(2):117-23. doi: 10.1016/j.ijantimicag.2015.11.012. Epub 2015 Dec 18. Int J Antimicrob Agents. 2016. PMID: 26774523

8

Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Calcagno A, Cusato J, D'Avolio A, Bonora S. Calcagno A, et al. Clin Pharmacokinet. 2017 Apr;56(4):355-369. doi: 10.1007/s40262-016-0456-6. Clin Pharmacokinet. 2017. PMID: 27641153 Review.

9

Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.

Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Focà E, et al. J Antimicrob Chemother. 2017 Nov 1;72(11):3163-3166. doi: 10.1093/jac/dkx274. J Antimicrob Chemother. 2017. PMID: 28961777

10

Precision medicine for HIV: where are we?

Cusato J, Allegra S, Nicolò A, Calcagno A, D'Avolio A. Cusato J, et al. Pharmacogenomics. 2018 Jan;19(2):145-165. doi: 10.2217/pgs-2017-0123. Epub 2017 Dec 5. Pharmacogenomics. 2018. PMID: 29202676 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page